Every material Form 8-K Charles River Laboratories filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Charles River reported third-quarter 2025 revenue of $1.00 billion, down 0.5% from $1.01 billion a year earlier, and non-GAAP diluted EPS of $2.43, down 6.2% from $2.59. GAAP diluted EPS was $1.10, down from $1.33, mainly due to a $0.33 per share loss on venture capital and strategic investments. The company narrowed its 2025 outlook to the middle and upper ends of its prior revenue and EPS ranges, with non-GAAP EPS now estimated at $10.10 to $10.30.
Q3 revenue was $1.00 billion, down 0.5%; organic revenue fell 1.6%.
Non-GAAP diluted EPS was $2.43, down 6.2% from $2.59; GAAP diluted EPS was $1.10 versus $1.33.
2025 non-GAAP EPS estimate is now $10.10 to $10.30, compared with $9.90 to $10.30 previously.
RMS segment revenue rose 7.9% to $213.5 million, while DSA revenue fell 2.3% to $600.7 million.
Chief Financial Officer Flavia H. Pease will resign effective September 29, 2025, to pursue another opportunity, and Michael G. Knell, the Chief Accounting Officer, will serve as interim CFO until a permanent successor is named. The company said her decision was not the result of any disagreement over financial statements, internal controls, operations, policies or practices, and it reaffirmed its 2025 revenue and non-GAAP earnings per share guidance first provided on August 6, 2025.
Flavia H. Pease resigns as CFO effective September 29, 2025, to pursue another opportunity
Michael G. Knell, age 49, joined the company in April 2017 and will serve as interim CFO, effective upon Pease's departure
The company has commenced a comprehensive search for a permanent CFO; Knell's compensation terms were not determined as of the filing date
2025 revenue and non-GAAP EPS guidance, previously provided August 6, 2025, was reaffirmed
Charles River reported second-quarter 2025 revenue of $1.03 billion, up 0.6% as reported but down 0.5% organically, and non-GAAP earnings per share of $3.12, up 11.4%. GAAP earnings per share fell to $1.06 from $1.74, mainly due to accelerated amortization and restructuring and legal costs. The company raised its full-year non-GAAP earnings per share guidance but lowered its GAAP earnings per share guidance.
Q2 revenue was $1,032.1 million, up 0.6% reported and down 0.5% organic; DSA segment organic revenue fell 2.4%.
Q2 GAAP net income available to common shareholders was $52.3 million, or $1.06 per share, versus $90.0 million, or $1.74 per diluted share, a year earlier.
2025 non-GAAP EPS guidance was raised to $9.90-$10.30 from $9.30-$9.80; GAAP EPS guidance was lowered to $4.25-$4.65 from $4.35-$4.85.
The company said the U.S. Department of Justice had closed the grand jury and parallel civil investigations into its NHP shipments.
Charles River Laboratories amended CEO James Foster's employment agreement on May 20, 2025, extending his term by one year to February 12, 2027, with all other terms unchanged. At the same meeting, shareholders re-elected seven directors, approved executive pay on an advisory basis, ratified PricewaterhouseCoopers as auditor, and rejected a PETA-submitted proposal on non-human primates.
Foster employment term extended one year to February 12, 2027; other terms unchanged
Seven directors elected to serve until the 2026 Annual Meeting; Steven Barg, Mark Enyedy, Abraham Ceesay and Paul Graves appointed to the Board
Advisory vote on executive compensation: 40,218,870 for and 1,432,240 against
PETA proposal on non-human primates not approved: 3,457,547 for and 38,051,509 against
Charles River Laboratories entered a Cooperation Agreement with activist investor Elliott Investment Management, which will add four new directors after the May 20, 2025 annual meeting and launch a comprehensive strategic review of the business. Four incumbent directors will not stand for re-election, and the board will be limited to 11 members while the agreement is in effect.
Steven Barg, Abe Ceesay, Mark Enyedy and Paul Graves join the board after the May 20, 2025 annual meeting, each for a term ending at the 2026 annual meeting.
Robert Bertolini, Deborah Kochevar, George Massaro and Richard Wallman will not stand for re-election at the 2025 annual meeting.
The Strategic Planning and Capital Allocation Committee will review the business and examine alternatives to enhance long-term stockholder value, then report to the full board.
The filing gives no financial results or guidance; the press release describes Elliott as the company's largest investor.
Charles River Laboratories reported first-quarter 2025 revenue of $984.2 million, down 2.7% from $1,011.6 million a year earlier, with GAAP diluted earnings per share of $0.50 versus $1.30. Non-GAAP diluted EPS rose 3.1% to $2.34, and the company raised its 2025 non-GAAP EPS guidance to $9.30 to $9.80 from $9.10 to $9.60, which matters to shareholders because revenue and GAAP profit declined while the outlook moved higher.
Q1 2025 revenue was $984.2 million, down 2.7% from $1,011.6 million; organic revenue fell 1.8%.
GAAP diluted EPS was $0.50 versus $1.30 in Q1 2024; non-GAAP diluted EPS was $2.34 versus $2.27.
2025 non-GAAP EPS guidance raised to $9.30 to $9.80 from $9.10 to $9.60; reported revenue guidance is now (5.5)% to (3.5)%.
The company repurchased $350 million of common stock in Q1 and had $549.3 million remaining on its $1.0 billion authorization as of March 29, 2025.
Charles River Laboratories reported fourth-quarter 2024 revenue of $1.00 billion, down 1.1%, and a GAAP loss of $4.22 per share after a $215.0 million goodwill impairment tied to its Biologics Solutions unit. Non-GAAP EPS rose 8.1% to $2.66 in the quarter, but full-year 2024 non-GAAP EPS fell 3.3% to $10.32, and the company guided to lower 2025 revenue and non-GAAP EPS of $9.10 to $9.60 while planning about $350 million in stock repurchases.
Q4 2024 revenue was $1.00 billion, down 1.1% from $1.01 billion; organic revenue declined 1.8%
Q4 GAAP loss per share was $(4.22), versus $3.62 diluted EPS a year earlier; the goodwill impairment accounted for $4.20 per share
2025 guidance: reported revenue decline of 7.0% to 4.5%; non-GAAP EPS of $9.10 to $9.60 versus $10.32 in 2024
Company plans to repurchase approximately $350 million of common stock in 2025
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Charles River Laboratories filing is on SEC EDGAR ↗. 8-K briefs of other companies →